Literature DB >> 19299661

Fragment-based ligand discovery.

Marcus Fischer1, Roderick E Hubbard.   

Abstract

From home building and decor to mass production, modular design is a standard feature of the modern age. The concept also promises to define drug discovery efforts in the near future, as a wide range of methodologies, from NMR to X-ray crystallography, are being adapted to high-throughput platforms. In particular, "fragment-based ligand discovery" describes the laboratory-driven evolution of drugs from libraries of chemical building blocks. "Evolution" is an apt word for the process, as a wide array of methods are used to define how compound fragments can be best fit into the binding sites of medically relevant target biomolecules. A number of compounds that evolved from fragments have entered the clinic, and the approach is increasingly accepted as an additional route to identifying new hit compounds in pharmaceutical discovery and inhibitor design.

Mesh:

Substances:

Year:  2009        PMID: 19299661     DOI: 10.1124/mi.9.1.7

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  17 in total

1.  Small molecules containing hetero-bicyclic ring systems compete with UDP-Glc for binding to WaaG glycosyltransferase.

Authors:  Jens Landström; Karina Persson; Christoph Rademacher; Magnus Lundborg; Warren Wakarchuk; Thomas Peters; Göran Widmalm
Journal:  Glycoconj J       Date:  2012-06-19       Impact factor: 2.916

2.  Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules.

Authors:  Warren R J D Galloway; Albert Isidro-Llobet; David R Spring
Journal:  Nat Commun       Date:  2010-09-21       Impact factor: 14.919

3.  Advances in Nuclear Magnetic Resonance for Drug Discovery.

Authors:  Robert Powers
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

4.  Fragment-based strategy for structural optimization in combination with 3D-QSAR.

Authors:  Haoliang Yuan; Wenting Tai; Shihe Hu; Haichun Liu; Yanmin Zhang; Sihui Yao; Ting Ran; Shuai Lu; Zhipeng Ke; Xiao Xiong; Jinxing Xu; Yadong Chen; Tao Lu
Journal:  J Comput Aided Mol Des       Date:  2013-11-01       Impact factor: 3.686

5.  Fragment Screening by NMR.

Authors:  Ben J Davis
Journal:  Methods Mol Biol       Date:  2021

6.  Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo.

Authors:  Oliv Eidam; Chiara Romagnoli; Guillaume Dalmasso; Sarah Barelier; Emilia Caselli; Richard Bonnet; Brian K Shoichet; Fabio Prati
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-05       Impact factor: 11.205

Review 7.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

Review 8.  High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists.

Authors:  Bainan Wu; Elisa Barile; Surya K De; Jun Wei; Angela Purves; Maurizio Pellecchia
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

Review 9.  Therapeutic approaches to preventing cell death in Huntington disease.

Authors:  Anna Kaplan; Brent R Stockwell
Journal:  Prog Neurobiol       Date:  2012-08-28       Impact factor: 11.685

10.  HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery.

Authors:  Bainan Wu; Ziming Zhang; Roberta Noberini; Elisa Barile; Marc Giulianotti; Clemencia Pinilla; Richard A Houghten; Elena B Pasquale; Maurizio Pellecchia
Journal:  Chem Biol       Date:  2013-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.